Filipe Moura, ESC 2022: A post-hoc analysis of the DECLARE-TIMI 58 and DAPA-CKD trials of dapagliflozin in patients with type 2 diabetes
Combining data from the DECLARE and DAPA-CKD trials enables the effect of dapagliflozin to be examined across a spectrum of baseline kidney function. In this touchCARDIO interview, we speak with Dr Filipe Moura (Brigham and Women’s Hospital, Harvard Medical School, Boston, USA) to discuss the post-hoc analysis of the DECLARE and DAPA-CKD data and the significance for clinical practice.
The abstract entitled ‘Effects of dapagliflozin on cardiovascular and kidney events by baseline eGFR and UACR in patients with type 2 diabetes mellitus: A patient-level pooled analysis of DECLARE-TIMI 58 and DAPA-CKD trials’ was presented at the European Society of Cardiology (ESC) Congress 2022, 26 – 29 August 2022.
- What was the purpose of the post-hoc analysis of the DECLARE and DAPA-CKD data? (0:21)
- What subgroups were evaluated in this study? (1:28)
- What were the findings in the different baseline eGFR and urinary albumin: creatinine ratio groups? (2:59)
- What is the significance of these findings for clinical practice? (5:11)
Disclosures: Filipe Moura has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Danielle Crosby.
Filmed as a highlight of ESC 2022
Access more content on Cardiovascular Risk here
Share this Video
Related Videos In Cardiovascular Disease
John Forrest, ACC 2023: Evolut low risk trial, transcatheter versus surgical aortic valve replacement in patients at low surgical risk
The Evolut low risk trial aimed to compare transcatheter versus surgical aortic valve replacement in patients who were at low risk for surgery. In this touchCARDIO interview, we speak with Dr John Forrest (Yale New Haven Hospital, Yale University, New Haven, CT, USA) to discuss the eligibility criteria, the key findings and the outlook for […]
John Forrest, ACC 2023: The treatment paradigm for patients with aortic stenosis
The treatment paradigm for aortic stenosis has developed dramatically in the past decade. In this touchCARDIO interview, we speak with Dr John Forrest (Yale New Haven Hospital, Yale University, New Haven, CT, USA) to outline and discuss the developments. Dr Forrest presented an abstract entitled ‘Transcatheter Versus Surgical Aortic Valve Replacement In Aortic Stenosis Patients […]
Steven Nissen, ACC 2023: Lipid-lowering therapies – current and future options
Many lipid-lowering therapies exist, such as statins to manage and reduce lipid levels. While statins are the most commonly used medication, some patients may need additional interventions to lower their LDL cholesterol levels. In this touchCARDIO interview, we speak with Prof. Steven Nissen (Cleveland Clinic, Cleveland, OH, USA) to explore current and developing novel lipid-lowering […]
Journal articles and more to your inbox
Get the latest clinical insights from touchCARDIOSign me up!